{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:43:33Z","timestamp":1790613813355,"version":"4.1.0"},"reference-count":70,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Hepatocellular carcinoma (HCC) arises in the background of chronic liver diseases, including hepatitis and liver cirrhosis caused by hepatitis C virus (HCV) infection. It is well known that HCV eradication using antiviral drugs can efficiently inhibit hepatocarcinogenesis. Recent advances in and development of direct-acting antiviral (DAA) drugs has revolutionized the treatment of HCV infection, and the vast majority of HCV patients can achieve HCV eradication using DAAs. However, mounting evidence clearly indicates that HCC inevitably occurs in a subset of patients after successful viral eradication using DAA therapy. Cancer is a genetic disease, and the accumulation of genetic and epigenetic aberrations may cause hepatocarcinogenesis in chronically damaged liver, even after virus elimination. In this review, we highlight HCC development after HCV eradication and discuss the current understanding of the molecular mechanisms of tumorigenesis after virus elimination, focusing on the genetic and epigenetic background of chronically damaged liver tissues.<\/jats:p>","DOI":"10.3390\/pathogens11040430","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T21:23:55Z","timestamp":1648848235000},"page":"430","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Clinical and Molecular Basis of Hepatocellular Carcinoma after Hepatitis C Virus Eradication"],"prefix":"10.3390","volume":"11","author":[{"given":"Natsumi","family":"Oe","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Red Cross Osaka Hospital, Osaka 5438555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruhiko","family":"Takeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto 6068501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4426-1491","authenticated-orcid":false,"given":"Yuji","family":"Eso","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto 6068501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Takai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto 6068501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Marusawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Red Cross Osaka Hospital, Osaka 5438555, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"key":"ref_1","unstructured":"Stewart, B.W., Weiderpass, E., and Wild, C.P. (2020). Liver cancer. World Cancer Report 2020, International Agency for Research on Cancer."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"European Association for The Study of The Liver (2012). EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol., 56, 908\u2013943.","DOI":"10.1016\/j.jhep.2011.12.001"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/jvh.13276","article-title":"Incidence of HCC in chronic hepatitis C patients with advanced hepatic fibrosis who achieved SVR following DAAs: A prospective study","volume":"27","author":"Shiha","year":"2020","journal-title":"J. Viral. Hepat."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1053\/j.gastro.2018.08.024","article-title":"Risk of Hepatocellular Cancer in Patients with Non-Alcoholic Fatty Liver Disease","volume":"155","author":"Kanwal","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_5","first-page":"S0168","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"17","author":"Ioannou","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of Hepatocellular Carcinoma in Patients with HCV-Associated Cirrhosis Treated with Direct-Acting Antiviral Agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.jhep.2015.02.006","article-title":"From non-A, non-B hepatitis to hepatitis C virus cure","volume":"62","author":"Pawlotsky","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/S0140-6736(98)07124-4","article-title":"Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)","volume":"352","author":"Poynard","year":"1998","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/hep.1840160307","article-title":"A pilot study of ribavirin therapy for chronic hepatitis C","volume":"16","author":"Shindo","year":"1992","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1002\/hep.24641","article-title":"An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases","volume":"54","author":"Ghany","year":"2011","journal-title":"Hepatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: Importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2018). EASL Recommendations on Treatment of Hepatitis C 2018. J. Hepatol., 69, 461\u2013511.","DOI":"10.1016\/j.jhep.2018.03.026"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/hepr.13501","article-title":"JSH Guidelines for the Management of Hepatitis C Virus Infection, 2019 Update; Protective Effect of Antiviral Therapy against Hepatocarcinogenesis","volume":"50","author":"Asahina","year":"2020","journal-title":"Hepatol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.510290439","article-title":"Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis","volume":"29","author":"Ikeda","year":"1999","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0140-6736(95)91739-X","article-title":"Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis","volume":"346","author":"Nishiguchi","year":"1995","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1053\/j.gastro.2016.12.021","article-title":"Unusually High Rates of Hepatocellular Carcinoma after Treatment with Direct-Acting Antiviral Therapy for Hepatitis C Related Cirrhosis","volume":"152","author":"Ravi","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/carcin\/bgy099","article-title":"The development of hepatocellular carcinoma in HCV-infected patients treated with DAA: A comprehensive analysis","volume":"39","author":"Huang","year":"2018","journal-title":"Carcinogenesis"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Lee, H.W., Han, D.H., Shin, H.J., Lee, J.S., Kim, S.U., Park, J.Y., Kim, D.Y., Ahn, S.H., and Kim, B.K. (2020). Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals. Cancers, 12.","DOI":"10.3390\/cancers12113414"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1002\/hep.29707","article-title":"The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study","volume":"67","author":"Li","year":"2018","journal-title":"Hepatology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of Hepatocellular Cancer in HCV Patients Treated with Direct-Acting Antiviral Agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3390\/livers1040024","article-title":"Predictive Factors for Hepatocellular Carcinoma Development after Direct-Acting Antiviral Treatment of HCV","volume":"1","author":"Jilkova","year":"2021","journal-title":"Livers"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased Risk for Hepatocellular Carcinoma Persists up to 10 Years after HCV Eradication in Patients with Baseline Cirrhosis or High FIB-4 Scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","article-title":"Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals","volume":"72","author":"Pons","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/jgh.15243","article-title":"Impact of liver-stiffness measurement on hepatocellular carcinoma development in chronic hepatitis C patients treated with direct-acting antivirals: A systematic review and time-to-event meta-analysis","volume":"36","author":"You","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.jhep.2020.11.021","article-title":"Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity","volume":"74","author":"Krassenburg","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jhep.2020.03.030","article-title":"Undefined\/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis","volume":"73","author":"Sangiovanni","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mashiba, T., Joko, K., Kurosaki, M., Ochi, H., Osaki, Y., Kojima, Y., Nakata, R., Goto, T., Takehiro, A., and Kimura, H. (2018). Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0194704"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2019.07.040","article-title":"Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated with Increased Survival in Patients with a History of Hepatocellular Carcinoma","volume":"157","author":"Singal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1002\/hep.30988","article-title":"Cure With Interferon-Free Direct-Acting Antiviral Is Associated with Increased Survival in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma from Both East and West","volume":"71","author":"Dang","year":"2020","journal-title":"Hepatology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1053\/j.gastro.2007.04.068","article-title":"Relationship between hepatic\/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects","volume":"133","author":"Gastaldelli","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Siphepho, P.Y., Liu, Y.T., Shabangu, C.S., Huang, J.F., Huang, C.F., Yeh, M.L., Yu, M.L., and Wang, S.C. (2021). The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101491"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"100090","DOI":"10.1016\/j.metop.2021.100090","article-title":"Non-alcoholic fatty liver disease is a risk factor for occurrence of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients: A prospective four-years follow-up study","volume":"10","author":"Ji","year":"2021","journal-title":"Metabol. Open"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1159\/000513705","article-title":"Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals","volume":"10","author":"Minami","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ogawa, E., Nomura, H., Nakamuta, M., Furusyo, N., Kajiwara, E., Dohmen, K., Kawano, A., Ooho, A., Azuma, K., and Takahashi, K. (2020). Development of Hepatocellular Carcinoma by Patients Aged 75-84 with Chronic Hepatitis C Treated with Direct-Acting Antivirals. J. Infect. Dis., jiaa359.","DOI":"10.1093\/infdis\/jiaa359"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.15403\/jgld.2014.1121.281.hpc","article-title":"Predictive factors for hepatocellular carcinoma occurrence or recurrence after direct-acting antiviral agents in patients with chronic hepatitis C","volume":"28","author":"Yoshimasu","year":"2019","journal-title":"J. Gastrointestin. Liver Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1053\/j.gastro.2017.10.035","article-title":"Levels of Cytokines in Serum Associate with Development of Hepatocellular Carcinoma in Patients with HCV Infection Treated with Direct-Acting Antivirals","volume":"154","author":"Debes","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-Term Risk of Hepatocellular Carcinoma in HCV Patients Treated with Direct Acting Antiviral Agents","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"ref_44","first-page":"e2843","article-title":"Hepatocellular Carcinoma Occurrence and Recurrence in Hepatitis C-Infected Patients Treated with Direct-Acting Antivirals","volume":"10","author":"Syed","year":"2018","journal-title":"Cureus"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.jhep.2018.07.024","article-title":"Development of models estimating the risk of hepatocellular carcinoma after antiviral treatment for hepatitis C","volume":"69","author":"Ioannou","year":"2018","journal-title":"J. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: The Catalogue of Somatic Mutations in Cancer","volume":"47","author":"Tate","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/ng.3547","article-title":"Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer","volume":"48","author":"Fujimoto","year":"2016","journal-title":"Nat. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1038\/nature08987","article-title":"International network of cancer genome projects","volume":"464","author":"Hudson","year":"2010","journal-title":"Nature"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/hep.27372","article-title":"Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis","volume":"60","author":"Nault","year":"2014","journal-title":"Hepatology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/ng.3252","article-title":"Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets","volume":"47","author":"Schulze","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/ng.804","article-title":"High-resolution characterization of a hepatocellular carcinoma genome","volume":"43","author":"Totoki","year":"2011","journal-title":"Nat. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1053\/j.gastro.2015.05.061","article-title":"Genetic Landscape and Biomarkers of Hepatocellular Carcinoma","volume":"149","author":"Villanueva","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Takeda, H., Takai, A., Eso, Y., Takahashi, K., Marusawa, H., and Seno, H. (2022). Genetic Landscape of Multistep Hepatocarcinogenesis. Cancers, 14.","DOI":"10.3390\/cancers14030568"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1053\/j.gastro.2013.09.025","article-title":"Leptin receptor somatic mutations are frequent in HCV-infected cirrhotic liver and associated with hepatocellular carcinoma","volume":"146","author":"Ikeda","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00535-019-01555-z","article-title":"Comprehensive analysis of genetic aberrations linked to tumorigenesis in regenerative nodules of liver cirrhosis","volume":"54","author":"Kim","year":"2019","journal-title":"J. Gastroenterol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/s41586-019-1670-9","article-title":"Somatic mutations and clonal dynamics in healthy and cirrhotic human liver","volume":"574","author":"Brunner","year":"2019","journal-title":"Nature"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.cell.2019.03.026","article-title":"Somatic Mutations Increase Hepatic Clonal Fitness and Regeneration in Chronic Liver Disease","volume":"177","author":"Zhu","year":"2019","journal-title":"Cell"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/path.5533","article-title":"Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution","volume":"252","author":"Takeda","year":"2020","journal-title":"J. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jhep.2020.01.019","article-title":"The landscape of gene mutations in cirrhosis and hepatocellular carcinoma","volume":"72","author":"Bird","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/S0002-9440(10)63495-5","article-title":"Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis","volume":"163","author":"Lee","year":"2003","journal-title":"Am. J. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1002\/hep.22110","article-title":"Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma","volume":"47","author":"Nishida","year":"2008","journal-title":"Hepatology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1053\/j.gastro.2013.10.056","article-title":"Hepatitis virus infection affects DNA methylation in mice with humanized livers","volume":"146","author":"Okamoto","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.canlet.2012.01.038","article-title":"Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma","volume":"342","author":"Pogribny","year":"2014","journal-title":"Cancer Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1053\/j.gastro.2019.02.038","article-title":"HCV-Induced Epigenetic Changes Associated with Liver Cancer Risk Persist after Sustained Virologic Response","volume":"156","author":"Hamdane","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1093\/carcin\/bgab014","article-title":"Oncogenic transcriptomic profile is sustained in the liver after the eradication of the hepatitis C virus","volume":"42","author":"Takeda","year":"2021","journal-title":"Carcinogenesis"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/15384101.2018.1460023","article-title":"Metabolic reprogramming enables hepatocarcinoma cells to efficiently adapt and survive to a nutrient-restricted microenvironment","volume":"17","author":"Cassim","year":"2018","journal-title":"Cell Cycle"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41586-019-1373-2","article-title":"A human liver cell atlas reveals heterogeneity and epithelial progenitors","volume":"572","author":"Aizarani","year":"2019","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.cell.2020.06.038","article-title":"Spatial Transcriptomics and In Situ Sequencing to Study Alzheimer\u2019s Disease","volume":"182","author":"Chen","year":"2020","journal-title":"Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00535-019-01639-w","article-title":"Risk of gastric cancer in the second decade of follow-up after Helicobacter pylori eradication","volume":"55","author":"Take","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1053\/j.gastro.2014.04.036","article-title":"Accumulation of somatic mutations in TP53 in gastric epithelium with Helicobacter pylori infection","volume":"147","author":"Shimizu","year":"2014","journal-title":"Gastroenterology"}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/4\/430\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:48:39Z","timestamp":1760136519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/11\/4\/430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["pathogens11040430"],"URL":"https:\/\/doi.org\/10.3390\/pathogens11040430","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]}}}